Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter 2 Inhibitors: Clinical and Biochemical Characteristics of 29 Cases
International Journal of Endocrinology · 04.07.2023 · 2023 · 1-7
DOI: 10.1155/2023/6615624 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Endocrinology, erschienen am 04.07.2023. Verfasst von G A Stamatiades und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Yale New Haven Health, Bridgeport Hospital, Bridgeport, CT 06610, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Context
Numerous reports suggest an association between SGLT2 inhibitors and DKA. Since the use of these drugs for diabetes has increased dramatically, identification of patients at greatest risk of this life-threatening complication is essential.
Objective
To describe the clinical and biochemical characteristics of all reported cases of DKA associated with SGLT2 inhibitor use in patients with type 2 diabetes mellitus and to identify potential risk factors.
Design
A retrospective case series was conducted between March 2013 and August 2019 using an electronic medical record search algorithm.
Results
25 patients met the criteria for DKA associated with SGLT2i use (total of 29 cases), 15 were female, average age was 54.24 years, and mean diabetes duration was 8.76 years. The majority of the patients (23 patients) had no history of prior DKA. Average blood glucose concentrations at presentation were 298.9 ± 152.7 mg/dl. Interestingly, nearly half of the episodes (14) met the criteria of euglycemic DKA (glucose
Autor:innen und Institutionen
- Department of Medicine, Yale New Haven Health, Bridgeport Hospital, Bridgeport, CT 06610, USA.
- Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA 15261, USA.
- Division of Endocrinology, Columbia University Medical Center, New York, NY 10032, USA.
ORCID-Profile: G A Stamatiades, A Sideri-Gugger, S K Majumdar
Förderung
- NIDDK NIH HHS
Zitieren
APA
Stamatiades, G. A., D'Silva, P., Elahee, M., Viana, G. M., Sideri-Gugger, A., & Majumdar, S. K. (2023). Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter 2 Inhibitors: Clinical and Biochemical Characteristics of 29 Cases. International Journal of Endocrinology, 2023, 1-7. https://doi.org/10.1155/2023/6615624
Vancouver
Stamatiades GA, D'Silva P, Elahee M, Viana GM, Sideri-Gugger A, Majumdar SK. Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter 2 Inhibitors: Clinical and Biochemical Characteristics of 29 Cases. International Journal of Endocrinology. 2023;2023:1-7. doi:10.1155/2023/6615624
BibTeX
@article{Stamatiades2023,
author = {Stamatiades, G A and D'Silva, P and Elahee, M and Viana, G M and Sideri-Gugger, A and Majumdar, S K},
title = {Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter 2 Inhibitors: Clinical and Biochemical Characteristics of 29 Cases},
journal = {International Journal of Endocrinology},
year = {2023},
volume = {2023},
pages = {1--7},
doi = {10.1155/2023/6615624}
}
EUVIMED